Indications/Uses
Listed in Dosage.
|
Dosage/Direction for Use
Adult: PO Nausea and vomiting associated w/ cancer chemotherapy 500 mcg 1 hr before therapy. IV Nausea and vomiting associated w/ cancer chemotherapy 250 mcg over 30 sec approx 30 min before therapy. Prophylaxis of postoperative nausea and vomiting 75 mcg over 10 sec before induction of anaesthesia.
|
Special Precautions
Patient w/ history of constipation, intestinal obstruction, history or risk of QT interval prolongation, electrolyte abnormalities. Childn. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, somnolence or fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs and symptoms of serotonin syndrome.
|
Adverse Reactions
Significant: QT prolongation, bradycardia, hypersensitivity reactions (e.g. anaphylaxis).
Nervous: Headache, dizziness, somnolence, fatigue, weakness, anxiety, vertigo, flu-like symptoms, insomnia, paresthesia.
CV: Nonsustained tachycardia, hypotension, HTN, MI, hot flush.
GI: Constipation, diarrhoea, abdominal pain, dyspepsia, dry mouth, hiccups, flatulence, anorexia.
Hepatic: Increased serum ALT/AST, bilirubin.
Genitourinary: Urinary retention.
Endocrine: Hyperkalaemia, electrolyte fluctuations, hyperglycaemia, metabolic acidosis, glycosuria.
Musculoskeletal: Arthralgia.
Ophthalmologic: Amblyopia.
Otic: Tinnitus.
Dermatologic: Pruritus, rash, allergic dermatitis.
Others: Inj site reaction.
Potentially Fatal: Rarely, serotonin syndrome (e.g. altered mental status, autonomic instability, neuromuscular symptoms). |
Drug Interactions
Decreased therapeutic effect of tramadol.
|
CIMS Class
|
ATC Classification
A04AA05 - palonosetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
|